Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 20:28:39时区推断·⟳ 抓取 20:30:30·⚡ 决策 07-22 22:34:34 +2h04m·97.3 天前
瑞博生物vortosiran慢性冠心病IIa期显示FXI活性最高平均下降92%
vortosiran在慢性CAD患者IIa期中显示剂量依赖、长效FXI抑制，高剂量400mg维持剂量下FXI活性平均最大降幅92%，且未见治疗相关严重不良事件。
📄 原文Investing.com↗ 原文
Ribo reports positive phase 2a trial data for vortosiran in CAD
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven? SHANGHAI and MOLNDAL, Sweden - Suzhou Rib…
不做 瑞博生物-B（06938.HK）
事件方向利好但仍是IIa早期数据，7月8日已预告披露且当日股价已涨6.2%，短期商业化收入增量不可量化，不追。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司预告将在7月22日CPIC首次披露vortosiran IIa临床数据并举行线上解读会。
- 港股收盘后中文财经媒体报道IIa积极结果和92% FXI活性平均最大降幅。
- 公司新闻稿确认IIa积极数据、400mg维持剂量、未见治疗相关严重不良事件。
- 英文稿向海外投资者扩散同一临床数据。
- 2026-07-22市场反应futu非一手瑞博生物-B（06938.HK）收53.95港元，较前收50.80港元上涨6.2%，成交额约2830万港元。
关键理由
- vortosiran在慢性CAD患者IIa期中显示剂量依赖、长效FXI抑制，高剂量400mg维持剂量下FXI活性平均最大降幅92%，且未见治疗相关严重不良事件。
- 公司仍是临床阶段创新药企业，本次为IIa期生物标志物/安全性数据，下一步还需ORBIT-XI多个IIb和III期验证，短期没有收入确认。
- 量级句：公司现阶段主要价值来自研发管线而非商业收入，本事件扩大远期抗血栓适应症期权，但从IIa到商业化仍需多年临床和注册投入，当前无法形成可落地收入或利润增量。
主要风险
- 公司7月8日已预告将在7月22日CPIC首次披露IIa数据，正式数据公布前股价当日已上涨6.2%，存在预期交易和见光后波动风险。
- FXI抑制赛道有小分子和其他抗凝机制竞争，IIa结果不等同于临床终点获益或商业化确定性。
反向证据
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- normalize_ticker · 结果未知
原文全文
展开原文 · 2,063 字
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
SHANGHAI and MOLNDAL, Sweden - Suzhou Ribo Life Science Co., Ltd. (06938.HK) announced today positive results from a phase 2a study evaluating vortosiran, an siRNA therapy targeting coagulation Factor XI, in patients with chronic coronary artery disease.
The randomized, double-blind, placebo-controlled study in Europe showed that vortosiran was generally well tolerated in patients receiving standard aspirin treatment and achieved dose-dependent suppression of FXI activity, according to a press release statement. The trial enrolled patients with chronic CAD and previous myocardial infarction.
Patients in the high dose group receiving a 400mg maintenance dose achieved a mean maximum reduction in FXI activity of 92%, which sustained for several months following dosing. The company stated this data supports dosing every three to six months in various indications.
No treatment-related serious adverse events, major bleeding events, or clinically relevant non-major bleeding events were observed during the study. The trial is registered as NCT06717074 on clinicaltrials.gov.
"These Phase 2a data, generated in the target patient population on top of standard of care, reinforce our belief that vortosiran is a safe and highly differentiated FXI-inhibition approach for thromboembolic diseases," said Dr. Li-Ming Gan, co-CEO and Global President of R&D at Ribo.
The company announced it has initiated the ORBIT-XI program, which includes several phase 2b trials designed to support progression into phase 3 development across multiple indications.
Vortosiran is a GalNAc-conjugated siRNA candidate that suppresses Factor XI synthesis. Suzhou Ribo Life Science is a clinical stage company focused on developing nucleic acid drugs based on RNA interference technology. Its subsidiary Ribocure Pharmaceuticals AB is dedicated to development of oligonucleotide therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SHANGHAI and MOLNDAL, Sweden - Suzhou Ribo Life Science Co., Ltd. (06938.HK) announced today positive results from a phase 2a study evaluating vortosiran, an siRNA therapy targeting coagulation Factor XI, in patients with chronic coronary artery disease.
The randomized, double-blind, placebo-controlled study in Europe showed that vortosiran was generally well tolerated in patients receiving standard aspirin treatment and achieved dose-dependent suppression of FXI activity, according to a press release statement. The trial enrolled patients with chronic CAD and previous myocardial infarction.
Patients in the high dose group receiving a 400mg maintenance dose achieved a mean maximum reduction in FXI activity of 92%, which sustained for several months following dosing. The company stated this data supports dosing every three to six months in various indications.
No treatment-related serious adverse events, major bleeding events, or clinically relevant non-major bleeding events were observed during the study. The trial is registered as NCT06717074 on clinicaltrials.gov.
"These Phase 2a data, generated in the target patient population on top of standard of care, reinforce our belief that vortosiran is a safe and highly differentiated FXI-inhibition approach for thromboembolic diseases," said Dr. Li-Ming Gan, co-CEO and Global President of R&D at Ribo.
The company announced it has initiated the ORBIT-XI program, which includes several phase 2b trials designed to support progression into phase 3 development across multiple indications.
Vortosiran is a GalNAc-conjugated siRNA candidate that suppresses Factor XI synthesis. Suzhou Ribo Life Science is a clinical stage company focused on developing nucleic acid drugs based on RNA interference technology. Its subsidiary Ribocure Pharmaceuticals AB is dedicated to development of oligonucleotide therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。